Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of November 2022. The report, dated November 14, 2022, incorporates by reference a press release (Exhibit 99.1) and is signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Key Financial Metrics
The provided filing text does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or details on unusual items. The document serves primarily as a cover for the referenced press release.
Investor Verification Checklist
- Review the full text of the press release dated November 14, 2022 (Exhibit 99.1) for specific operational or clinical updates.
- Verify the incorporation of this report into the Form F-3 registration statement (File No. 333-252074).
- Check subsequent filings for any superseding information regarding the matters referenced in this report.